03.10.2007 12:00:00

Pfizer Hires New Vice President and Chief Talent Officer

Pfizer announced today that Dr. Tanya Clemons, a senior executive with extensive experience in leadership and organization change at Microsoft and IBM, will join Pfizer as vice president and Chief Talent Officer in November. Dr. Clemons will report to Mary McLeod, the senior vice president for Worldwide Talent Development and Human Resources. She will be a member of the Human Resources Leadership Team and Pfizer’s Senior Management Team. Dr. Clemons will have responsibility for enterprise-wide organization development, talent and learning strategies and play a critical role in shaping the new culture. In this role, she will lead the company’s senior executive talent development, global people development and succession processes with emphasis on identification, retention, and development of executive level incumbent, replacement and high potential individuals. "At Pfizer, we have some of the best leaders in the industry and we have very high expectations of them and of all of our colleagues. We’re investing more in our talent pipeline and making an ongoing commitment to developing our people,” said Mary McLeod. "Tanya’s depth of expertise and her practical experience designing and implementing global processes and programs will be a real asset to our business as we continue to implement our growth strategy.” Dr. Clemons is currently the corporate vice president for People and Organization Capability at Microsoft where she is responsible for leadership development, talent management, employee learning and training, organization development, and enterprise-wide change initiatives. Prior to joining Microsoft, she held leadership roles at IBM, Georgia-Pacific and Anheuser-Busch. Dr. Clemons earned a B.A. in psychology from the University of New Orleans and a Ph.D. in organizational psychology from Louisiana State University.
JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.

Analysen zu Pfizer Inc.mehr Analysen

19.12.24 Pfizer Neutral UBS AG
17.12.24 Pfizer Buy Jefferies & Company Inc.
17.12.24 Pfizer Neutral UBS AG
17.12.24 Pfizer Neutral JP Morgan Chase & Co.
12.12.24 Pfizer Neutral JP Morgan Chase & Co.
Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Pfizer Inc. 26,11 0,38% Pfizer Inc.

Indizes in diesem Artikel

Dow Jones 41 938,45 -1,63%
S&P 500 5 827,04 -1,54%
S&P 100 2 857,98 -1,56%
NYSE US 100 16 447,86 0,76%